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Abstract 
Background  
Anxiety is a common and distressing problem after stroke. A previous systematic review of 
observational studies [1] included 44 studies published to March 2011. The review needed updating: 
there were known to be more recent primary studies of anxiety after stroke and some sub-group 
analyses had previously been based on small samples, with resultant imprecision.  
Aims 
To undertake an updated systematic review and meta-analysis of observational studies of anxiety 
after stroke and integrate the findings with those reported previously. 
Summary of review 
Multiple databases were searched to May 2018 and 53 new studies were included following dual 
independent sifting and data extraction. These were combined with 44 previous studies to form a 
combined dataset of 97 studies, comprising 22,262 participants. Studies using interview methods 
were of higher quality. Rates of anxiety by interview were 18.7% (95% CI 12.5, 24.9%) and 24.2% 
(95% CI 21.5, 26.9%) by rating scale. Rates of anxiety did not lower meaningfully up to 24 months 
after stroke. Eight different anxiety sub-types were also reported.   
Conclusions  
The updated review has confirmed that anxiety occurs in around 1 in 4 patients (by rating scale) and 
1 in 5 patients (by interview). More research on anxiety sub-types is needed for an informed 
understanding of its effects and the development of interventions.  
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Background 
Mood problems are common after stroke with reported rates of depression, apathy and distress 
significantly higher than in the general population [2,3]. Anxiety is common in the general 
population [4] but its presence in stroke patients has been relatively under-recognised both in 
clinical and research settings. A systematic review of observational studies [1] included 44 studies 
and reported rates of anxiety as 18.3% when diagnosed by interview and 24.3% by rating scale. The 
review reported that rates lowered with time after stroke, although they remained higher than in 
the general population [4]. However the inclusion of relatively small numbers of studies at some 
time points meant that there was considerable imprecision in rates. Furthermore studies had also 
used a number of different scales and cut-off scores to define anxiety, producing considerable 
uncertainty around the true rate.  
More recent research has argued for the importance of subtypes of anxiety (for example, panic 
disorder; specific or simple phobias) for understanding its impact and for developing and delivering 
suitable interventions [5] or adapting those shown to be effective in the general adult population 
[6]. Our review in 2013 had recorded sub-types when they were reported in primary studies but this 
information was available in only 3 of the 8 relevant studies.  
Our review of 44 studies had searched databases until March 2011 and we are aware of the 
publication since then of further, potentially relevant studies. Another recent review in this area [7] 
was limited to publications over 2011-17, from a small range of languages, and only those using self-
report measures of anxiety. Consequently, updating the Campbell-Burton (2013) review [1] could 
have several potential benefits, not only making the findings more current but also potentially 
increasing the sample size and precision, particularly on sub-group analyses. Therefore the aims of 
this study were to undertake an updated systematic review of observational studies of anxiety after 
stroke; to integrate the findings with those previously reported [1]; and to disaggregate rates of 
anxiety by sub-type, rating scale and time after stroke.  
 
Method 
This review and the original systematic review [1] were both undertaken according to the PRISMA 
guidelines [8]. The review update protocol was registered on PROSPERO: CRD42018093718. 
Inclusion / exclusion criteria 
Studies were included if undertaken in populations or groups of patients with a clinical diagnosis of 
haemorrhagic or ischaemic stroke or transient ischaemic attack (TIA) and were assessed for 
symptoms of anxiety on a rating scale such as the Hospital Anxiety and Depression Scale (HADS) [9] 
or were diagnosed by clinical interview. We translated papers published in languages other than 
English if the title and abstract indicated potential eligibility.  We excluded studies if they: 
 used proxy measures of anxiety; 
 were intervention studies;  
 were limited to patients with subarachnoid haemorrhage or other specific stroke sub-types 
or demographic characteristics; 
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 were not designed to screen expressly for anxiety, or used non-specific measures of 
psychological distress;  
 used retrospective recruitment or mood reporting;  
 employed convenience sampling;  
 reported anxiety as a continuous outcome and we could not derive a categorical 
assessment. 
Study identification and data extraction 
We searched the following digital databases: Medline, Embase, CINAHL, PsycINFO, Allied and 
Complementary Medicine and Proquest dissertation, using a search strategy developed in Medline 
(see Appendix 1) and adapted to the other databases. We restricted the search to studies published 
from January 2009 (to ensure relevant studies were not missed) to May 2018 and applied no 
language restrictions. The search was undertaken by one investigator (ADR) and screening of title 
and abstract was undertaken by ADR with a second reviewer (NS) and decisions taken against the 
selection criteria. Independent data extraction was performed by two reviewers (two of: ADR, NS, 
PK) for all eligible studies.   
Quality of evidence 
We extracted information on study design, setting and patient characteristics. Study quality was 
assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies [10], see Appendix 2, which 
includes eight criteria. One criterion (comparability of cohorts) was recorded as not applicable 
because the included studies were all reporting prevalence rates derived from a single cohort. Study 
quality was not used to determine inclusion. Finally we assessed the quality of the 44 studies 
included in the original review using the NOS measure.  
Data synthesis 
We combined the studies reported in the 2013 review with those identified in the update.  
Studies were grouped into two categories based on method of case ascertainment: those using 
clinical interview for diagnosis; and those using a rating scale. We also extracted data on rates: at 
five different time points after stroke (up to 1 month; 1-5 months; 6-12 months; 12-24 months; over 
24 months) and did this separately for interview and rating scale studies; from different rating scales 
or different caseness thresholds on the same scale (using whatever had been used in the primary 
data study); and, for interview-based studies only, rates of anxiety sub-types. 
We undertook several meta-analyses. We excluded from pooling one study [11] using the  
hierarchical diagnostic rule in the Diagnostic and Statistical Manual-III (DSM-III) [12], meaning that 
anxiety is not diagnosed in the presence of depression, which may falsely deflate the reported rate 
of anxiety. For studies using rating scales we used whatever caseness threshold had been used by 
the primary researchers. When studies reported rates of anxiety at more than one time period, we 
used the first-reported time period as the primary outcome prevalence rate.      
The random effects model was used to summarize data. Chi-square was used to test for subgroup 
differences, and heterogeneity among the studies was assessed by the I-squared statistic. We used 
Review Manager 5.3 [13] for data analysis.   
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Results 
The search from 2009 to 2018 produced 22,564 unique references (see Figure 1), of which 53 met 
the inclusion criteria and had not been included in the 2013 review, including three translated from 
non-English language publications. The following results are based on the integrated data set of 97 
studies, comprising 44 studies from the original review [11, 14-58] and 53 studies from the update 
[59-114] (see Table 1).  
Figure 1. PRISMA flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Sc
re
e
n
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Records identified through 
database searching  
(n = 28,565) 
Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed  
(n = 22,564) 
Records screened  
(n = 22,564) 
Records excluded  
(n = 22,242) 
Full-text articles 
assessed for eligibility  
(n = 320) 
Full-text articles excluded, 
with reasons  
(n = 242) 
• Reported anxiety 
score as continuous 
(n = 84) 
• Did not measure 
prevalence of anxiety 
after stroke (n = 78) 
• Limited to patients 
with SAH or some 
other select 
characteristic n = 32) 
• Used non-
representative or 
retrospective 
sampling (n = 16) 
• Full text not available 
(n = 14) 
• Non-English language 
(n = 11) 
• Used non anxiety-
specific measures (n = 
4) 
• Non-observational 
study (n = 3) 
• Used retrospective 
sampling (n = 0) 
Studies included  
(n = 53) 
 5 
 
Figure 1: Meta-analysis of anxiety prevalence when diagnosed by interview 
 
 
 
Study characteristics 
The 97 studies included 26,262 participants and had been published between 1984 and 2018. Most 
had recruited patients from hospital (52), while other settings were rehabilitation (19), general 
population (15), a combination of settings (2) or not reported (8). Most studies were cross-sectional 
(78) or longitudinal cohort in design (15), although one used a case-control design and the design 
was not reported in two cases. Cohort studies included a range of data collection time points: 2 time 
points (n=4); 3 time points (n=4); 4 time points (n=4); 5 time points (n=2); 13 time points (n=1). 
Anxiety was recorded in patients in a very wide range of time periods after stroke (from 2 weeks to 
10 years).  
The studies had been undertaken in 34 different countries: UK (18); Netherlands (5); Norway, Italy, 
China and Australia (4 each); Sweden, Nigeria, Japan, India, Ireland, New Zealand, and Bosnia & 
Herzogovina (3 each); Thailand, Switzerland, South Korea, USA, Hong Kong and Croatia (2 each); and 
Benin, Brazil, Spain, Ukraine, Bahrain, Turkey, Tanzania, Finland, Slovakia, Georgia, Russia, France 
and Germany (1 each). Two studies were undertaken in more than 1 country; the country of origin 
was not reported in 6 studies.     
Measurement and assessment of anxiety 
Clinical diagnoses of anxiety disorder were made in 10 studies in accordance with different versions 
of the DSM (3 studies used the DSM-III [12]; 2 the DSM-III-R [115]; 5 used the DSM-IV [116]). The 
remaining studies used other interview methods: Structured Clinical Interview for DSM-V (SCID) 
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[117]; Schedules for Clinical Assessment in Neuropsychiatry (SCAN) [118]; Mini-International 
Neuropsychiatric Interview-Plus (MINI-Plus) [119]; and the CCND-3 [114]. Anxiety prevalence was 
reported in the interview studies from samples ranging from 50 to 350 participants (total 3,109; 
median 149.5).   
Nine different standardised scales were used to identify anxiety symptoms and generate caseness 
rates in 78 studies: the Generalised Anxiety Disorder (GAD) [120] (n=1); Hospital Anxiety and 
Depression Scale (HADS)-Anxiety subscale [9] (n=50); Hamilton Anxiety Rating Scale (HAM-A) [121] 
(n=7); Neuropsychiatric Inventory (NPI) [122] (n=1); Zung Self-rated Anxiety Scale [123] (n=3); 
Irritability Depression and Anxiety Scale, Anxiety subscale (IDA-A) [124] (n=1); Beck Anxiety 
Inventory (BAI) [125] (n=2); Adult Manifest Anxiety Scale (AMAS) [126] (n=1); and the General Health 
Questionnaire (GHQ-60 anxiety sub-scale) [127] (n=1). In addition, one study used a single question 
measure of anxiety, and another used a series of five researcher-developed questions.  Three of 
these scales (HADS-A; BAI; HAM-A) were used with more than one caseness threshold. In total 20 
different combinations of standardised scales and thresholds were used in the included studies. 
Anxiety prevalence was reported in the rating scale studies from samples ranging from 15 to 4,079 
participants (total 23,153; median 81).     
Anxiety prevalence 
The overall prevalence of anxiety when assessed by interview ranged from 0.6% to 33.3% in the 
primary studies. The updated pooled prevalence derived from the 18 included studies was 18.7% 
(95% confidence interval 12.5 to 24.9%), see Figure 2. Heterogeneity among the included studies 
was very high (97%).  
The assessment of anxiety by rating scale produced rates in the range 4.8% to 63.6% in the 78 
included studies. The overall frequency of anxiety ‘caseness’ by rating scale was 24.2% (95% CI 21.5 
to 26.9%), see Figure 3. Heterogeneity among the included studies was very high (95%).  
Given the difference in prevalence rates obtained from the interview and rating scale studies, we did 
not calculate a rate combining data from the two study types. 
Pooled anxiety prevalence at different times after stroke 
Pooled rates of anxiety in the acute phase (within 1 month of stroke) were reported as 15.5% (95% 
CI 6.3 to 24.7%) in seven studies using interview, and as 25.5% (95% CI 18.6 to 32.3%) in 19 studies 
using rating scales.  
Between 1 and 5 months after stroke rates of anxiety by interview were 21.4% (95% CI 19.2 to 
23.5%) in eight studies using interview methods, and 23.6% (95% CI 18.9 to 28.2%) in 24 studies 
using rating scales.  
In the 6-12 months period three studies used interviews methods and estimated the pooled 
prevalence as 31.8% (95% CI 17.8 to 27.3%), whereas 17 studies used rating scales and found the 
rate to be 21.5% (95% CI 15.3 to 27.8%).  
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Between 12 and 24 months after stroke only one study used interview methods to report a rate of 
11.0% (95% CI 3.5 to 18.5%), whereas 11 studies used rating scale methods and found an overall rate 
of 26.6% (95% CI 16.8 to 36.3%).   
In the period 24 months to 10 years the rate was reported in 3 studies using interview (20.4%; 95% 
CI 14.6 to 26.2%) and 10 studies using rating scales (26.0%; 95% CI 18.1 to 34.0%).   
 
Anxiety prevalence using different caseness thresholds on rating scales 
The rates obtained from meta-analysis were calculated for all combinations of standardised scales 
and thresholds; however in many cases only one or two studies were included per combination. 
Higher numbers per combination were available for the HADS-Anxiety scale, although seven 
different thresholds had been used and only two (>7 and >10) were reported in at least 10 studies. 
The reported pooled rates for each HADS-A caseness threshold are as follows: threshold >4, n=3 
studies, 37.3% (17.8 to 56.8%); >5, n=2, 27.9% (0.4 to 55.3%); >6, n=1, 4.1% (1.4 to 6.8%); >7, n=27, 
25.6% (20.9 to 30.3%); >8, n=2, 13.9% (-5.8 to 33.6%); >9, n=2, 29.1% (21.6 to 36.5%); >10, n=13, 
18.9% (14.4 to 23.4%).  
Anxiety sub-type caseness 
Among the 19 studies that used interview methods to reach a definition of anxiety caseness, 10 also 
reported the rate of anxiety sub-types.  
Agoraphobia was reported in four studies: 8.3% [43], 16.0% [45], 11.5% [47], 5.5% [103], and had a 
pooled prevalence of 8.4% (95% CI 6.5 to 10.4%; 1 squared =82%). Social phobia was reported just 
twice: 2.9% [47]; 2.1% [103], with a pooled prevalence of 2.3% (95% CI 0.9 to 3.7%; I squared 0%). 
Simple phobia was reported in three studies: 5.0% (OCSP-II), 8.7% [47], 2.1% [103], having a pooled 
prevalence of 2.1% (95% CI 1.5 to 4.3%; I squared 68%).  Rates of Obsessive-Compulsive Disorder 
(OCD) were reported in two studies: 1.9% [47] and 2.1% [103], with a pooled prevalence of 2.0% 
(95% CI 0.8 to 3.2%; I squared 0%). Finally, panic disorder was reported in four studies: 2.0% [43], 
17.3% [93], 10.6% [47] and 3.1% [103], with a pooled prevalence of 3.7% (95% CI 2.4 to 5.0%; I 
squared 90%).  
Generalised Anxiety Disorder (GAD) was reported in eight studies [43, 45, 47, 59, 73, 81, 86, 103]. 
However, a pooled prevalence was not calculated because in some studies it is not clear if GAD had 
been reported as a sub-type of anxiety or as a generic anxiety diagnosis. Similarly rates were not 
pooled for Phobic Disorder, which was reported in three studies [59, 73, 101], because it is unclear 
whether the category ‘phobic disorder’ includes all types of phobias or is a distinct phobia sub-type.   
Quality ratings of studies 
Studies were rated on the seven relevant items of the NOS scale [10], with each item ranked as low 
or high risk of bias. Among the 97 studies low risk of bias was assigned to scale items ranging from 1 
out of 7 to 6 out of 7 items (median 4/7). In studies using interview methods the range was 2/7 to 
6/7 (median 4/7), and in studies using rating scale methods low risk of bias ranged from 1/7 to 5/7 
items (median 4/7). Studies using interview methods had lower risk of bias than studies using rating 
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scales (Mann-Whitney U = 436.5; z = -2.763; p = .0058). Rates of low risk of bias varied considerably 
across the seven scored items. All 97 studies had low risk for length of follow-up, 83 for 
ascertainment of exposure, and 81 for representativeness of the exposed cohort. Low risk was 
present for 62 studies on adequacy of follow-up. Few studies had low risk of bias for the remaining 
three items: outcome assessment (n=20); anxiety shown not to be present at the study start (n=10); 
and selection of the non-exposed cohort (n=4). 
 
Discussion  
Brief summary of the findings 
This updated systematic review included 53 studies, which were combined with the 44 studies 
included in the 2013 review [1]. The 97 primary data studies included 19 studies using interview 
methods and 78 studies using rating scales. The pooled prevalence of anxiety after stroke was 18.7% 
when diagnosed by interview and 24.2% by self-report rating scale, confirming the rates reported in 
the previous review and also confirming the previously reported pattern of lower rates when using 
interview. Increasing the number of studies in the data pooling produced increased rate precision, 
particularly for interview studies. Rates of anxiety were relatively stable in the years after stroke. 
Strengths and weaknesses of the study 
The updated and combined review used a number of systematic review methods that increase 
review rigour and tend to reduce bias: searching of multiple databases; dual, independent screening 
used to determine entry criteria and for extraction; no language or date limits were applied; 
included studies were assessed for quality; and data pooling was used and reported when 
appropriate. We searched ProQuest for dissertations, and included conference abstracts, but 
otherwise did not search for unpublished studies 
The included primary data studies varied in quality, although study quality was not used as an entry 
criterion to the review. Studies using interview methods tended to be higher quality. Primary studies 
were included from many countries, although all studies except three were reported in English; this 
reflects a common finding in systematic reviews, although it is unclear if this would produce a 
reporting bias similar to that reported in reviews of intervention studies.  
Combining the studies found with those reported in the 2013 review allowed further data pooling, 
although in some cases the pooled estimates were based on small numbers of primary data studies, 
and levels of heterogeneity were often very high. Rates were reported using a range of different 
interview methods and ratings scales (and cut-off scores); data pooling for the overall prevalence 
calculations used whatever cut-off and timing had been reported in the primary study, which 
inevitably led to the combination of a variety of methods and reported rates. However it was 
thought that this potential disadvantage was offset by the advantage gained by increased overall 
sample size; the rates have now been calculated using aggregate samples of 3,109 (in interview 
studies) and 23,153 (in rating scale studies). 
 9 
 
We excluded studies reporting proxy ratings of anxiety as the focus of the review was on self-rating. 
However one consequence is the exclusion of studies of patients with strokes causing severe 
cognitive or language impairment, limiting the review’s external validity.     
What this review adds 
Updating the review led to the addition of a large number of studies published up to 2018, allowing 
rates to be estimated from 19 studies (for interview) and 78 studies (for rating scale), resulting in 
increased precision in estimates. Caseness rates generated by interview are confirmed as 
meaningfully lower than those generated by rating scale (on average anxiety is shown to occur in 1 
in 5 patients rather than 1 in 4), a direction of difference replicating that seen in depression after 
stroke [2,3]. The update confirmed that anxiety continues to be prevalent many years after stroke 
onset. The review update also allowed the calculation of rates for some anxiety sub-types such as 
panic disorder and phobias, which were shown to vary considerably, supporting the view [5] that 
this diagnostic detail is essential for an informed understanding of the phenomenon and 
development of effective interventions. However it is notable that only small numbers of studies 
reported sub-types; for example, rates of social phobia and OCD were based on just two studies with 
a combined sample size of 293. In some studies it was not clear whether sub-types were 
differentiated from a generic anxiety diagnosis.    
Implications for research 
This updated review has included almost 100 studies and 26,262 participants, reporting the rate of 
anxiety after stroke, although in the case of some primary studies, this was not their main objective. 
Almost 80 studies reported the rate of anxiety by rating scale and there seems little value in further 
new studies adding to this total. However there remains little evidence on rates of anxiety more 
than 12 and 24 months after stroke. A crucial advantage in future research would be gained by 
greater consensus on the rating scale (and its threshold for caseness) providing the most robust 
indication of anxiety after stroke: for example, receiver-operated characteristic (ROC) analysis of 
studies using interviews and rating scales could provide this. Further studies into anxiety sub-types 
(diagnosed by interview) would provide a useful addition to the published research. Similarly further 
studies assessing which factors tend to be associated with the onset and/or persistence of anxiety 
after stroke are warranted; quantitative and qualitative research could both make contributions to 
answering this important question.       
Implications for practice 
The updated review has confirmed the high rate of prevalence of anxiety after stroke and also 
confirmed that rates are sustained beyond the early months after stroke; that is, beyond what could 
be termed the initial reaction to stroke onset and discharge home after hospital admission. This 
suggests it is important to continue to assess or screen for anxiety 12 months or more after stroke 
onset, although the continued lack of evidence for interventions in this patient group does preclude 
evidence-based decisions about treatments if anxiety is identified [129]. Anxiety continues to be a 
problem for many patients, which also has implications for the mood and quality of life of unpaid 
carers [130], and its rate is similar to that of depression after stroke. Anxiety sub-types reported in 
this review tend to have a relatively low prevalence but their presence confirms the impact of 
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mental health problems, which may compound any physical and cognitive effects of the stroke as 
well as cause distress.  
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Appendix 1: Search strategy for MEDLINE database 
1. exp Cerebrovascular Disorders/ 
2. stroke*.mp 
3. (poststroke* or post-stroke* or cva*).mp 
4. (cerebrovasc* or brain vasc* or cerebral vasc*).mp 
5. ((cerebr* or brain* or cerebellar* or cerebellum* or vertebrobasilar*) adj2 (infarct* or 
ischemi* or ischaemi* or thrombo* or emboli* or apoplex* or occlus*)).mp 
6. ((cereb* or brain* or intracereb* or intracrani* or subarachnoid) adj2 (haemorrhag* or 
hemorrhag* or h?ematoma* or bleed*)).mp 
7. Hemiplegia/ or exp Paresis/ 
8. (hemipleg* or hemipar* or paresis or paretic).mp 
9. Or/1-8 
10. exp Adjustment Disorders/ 
11. exp Anxiety Disorders/ 
12. exp Neurotic Disorders/ 
13. Mental Disorders/ 
14. anxiet*.mp 
15. distress*.mp 
16. mood.mp 
17. (affect or affective) adj2 disorder.mp 
18. (neuros?s or neurotic*).mp. 
19. (depersonalization or depersonalisation or derealization or derealisation).mp. 
20. fear.mp. 
21. (worry* or worri* or apprehens*).mp 
22. (tension* adj2 symptom*).mp 
23. ((avoidanc* or avoidant*) adj2 (behaviour or behavior or symptom*)).mp.  
24. (autonomic adj2 (arousal* or symptom*)).mp.  
25. (hyperventil* adj2 (symptom* or syndrom*)).mp. 
26. (HADS or GHQ or STAI) 
27. Or/10-26 
28. 9 and 27 
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Appendix 2: Newcastle-Ottawa Quality Assessment Scale: Cohort Studies (Wells et al, 2018) 
 
1) Representativeness of the exposed cohort 
2) Selection of the non-exposed cohort  
3) Ascertainment of exposure 
4) Demonstration that outcome of interest was not present at start of study 
5) Comparability of cohorts on the basis of the design or analysis 
6) Assessment of outcome  
7) Was follow-up long enough for outcomes to occur 
8) Adequacy of follow up of cohorts 
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Table 1: Risk of bias assessment for studies using interviews 
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Ajiboye (2013) ★ ☆ ★ ☆ N/A ★ ★ ☆ 4/7 
Astrom (1996) ★ ☆ ★ ☆ N/A ★ ★ ★ 5/7 
Chinchaladze 
(2013) ☆ ☆ ☆ ☆ N/A ★ ★ ☆ 2/7 
Chun (2018) ★ ☆ ★ ☆ N/A ★ ★ ☆ 4/7 
Garikimukku 
(2015) ☆ ☆ ☆ ★ N/A ★ ★ ☆ 3/7 
Kneebone 
(2016) ★ ☆ ★ ☆ N/A ★ ★ ☆ 4/7 
Leppavuori 
(2003) ★ ☆ ★ ★ N/A ★ ★ ★ 6/7 
Morris (1990) ★ ☆ ★ ☆ N/A ★ ★ ★ 5/7 
Mumladze 
(2016) ☆ ☆ ☆ ☆ N/A ★ ★ ★ 3/7 
OCSP (House 
1991) and 
OCSP-II (Sharpe 
1990) 
★ ☆ ★ ★ N/A ★ ★ ★ 
6/7 
Oni (2016) ★ ★ ★ ☆ N/A ★ ★ ★ 6/7 
PCSS (Burvill 
1995) ★ ★ ★ ★ N/A ★ ★ ☆ 6/7 
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Petrova (2012) ★ ☆ ★ ☆ N/A ★ ★ ★ 5/7 
Sagen (2009) ★ ☆ ★ ☆ N/A ★ ★ ☆ 4/7 
Schottke (2015) ★ ☆ ★ ☆ N/A ★ ★ ☆ 4/7 
Schultz (1997) ★ ☆ ★ ☆ N/A ★ ★ ☆ 4/7 
Tang (2002) ★ ☆ ★ ☆ N/A ★ ★ ★ 5/7 
Verma (2012) ☆ ☆ ★ ☆ N/A ★ ★ ★ 4/7 
Zhang (2011) ☆ ☆ ☆ ☆ N/A ★ ★ ★ 3/7 
Key: ★, low risk of bias; ☆, high risk of bias; N/A, not applicable  
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Table 2: Risk of bias assessment for studies using rating scales 
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Ahlsio (1984) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
South London 
Stroke Register 
(Crichton, 2016; 
Ayerbe, 2014)   
★ ☆ ★ ☆ N/A ☆ ★ ☆ 
3/7 
Azanmasso 
(2017) ☆ ☆ ☆ ☆ N/A ☆ ★ ☆ 1/7 
Barker-Collo 
(2007) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Barker-Collo 
(2017) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Beghi (2009) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Bergerson 
(2010) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Bovim (2016) ☆ ☆ ☆ ☆ N/A ☆ ★ ☆ 1/7 
Bruggiman 
(2006) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Broomfield 
(2014) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Broomfield 
(2015) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Buijck (2012) ★ ☆ ☆ ☆ N/A ☆ ★ ☆ 2/7 
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Carod-Artal 
(2009) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Castellanos-
Pinedo (2011) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Chanchaem 
(2013) ☆ ☆ ☆ ☆ N/A ☆ ★ ☆ 1/7 
Crowley (2017) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
D’Alisa (2005) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
D’Aniello (2014) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
De Weerd 
(2011) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
De Weerd 
(2012) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Delva (2017) ★ ☆ ☆ ★ N/A ☆ ★ ☆ 3/7 
DeWit (2008) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Donnellan 
(2010) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Donnellan 
(2016) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Elf (2016) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Field (2008) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
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Fure (2006) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Galligan (2016) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Gangstad 
(2005) ★ ☆ ☆ ☆ N/A ☆ ★ ★ 3/7 
Ghika-Scmid 
(1999) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Giaquinto 
(1997) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Gillespie (1997) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
HSRS (Ueki, 
1999) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Huzmeli (2017) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Ibrahimagic 
(2005)  ☆ ★ ★ ☆ N/A ☆ ★ ☆ 3/7 
Ibrahimagic 
(2013) ☆ ☆ ★ ☆ N/A ☆ ★ ☆ 2/7 
Jones (2012) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Kim (2012) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Kootker (2016) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Knapp (1998) ☆ ☆ ☆ ☆ N/A ☆ ★ ★ 2/7 
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Langhorne 
(2000) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Li (2006) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Lincoln (1997) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Lincoln (2013) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Liu (2018) ★ ☆ ★ ★ N/A ☆ ★ ☆ 4/7 
Macniven 
(2005) ☆ ☆ ★ ☆ N/A ☆ ★ ★ 3/7 
Masskulpan 
(2008) & 
Kuptniratsalkul 
(2009) 
★ ☆ ★ ☆ N/A ☆ ★ ★ 
4/7 
Mellon (2013) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Merriman 
(2007) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Mihalov (2016) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Moon (2004) ★ ☆ ★ ★ N/A ☆ ★ ★ 5/7 
Morrison (2000; 
2005) ★ ☆ ☆ ☆ N/A ☆ ★ ★ 3/7 
Mulroy (2012) ☆ ☆ ☆ ☆ N/A ☆ ★ ☆ 1/7 
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Mutai (2017) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Nakling (2017) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
NEMSIS (Sturm, 
2004; Paul, 
2006) 
★ ☆ ★ ☆ N/A ☆ ★ ★ 
4/7 
Nijsse (2017) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Ojagbemi 
(2017) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Ponchel (2016) ★ ☆ ★ ☆ N/A ☆ ★ ☆ 3/7 
Raju (2010) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Sampson (2003)  ★ ★ ★ ☆ N/A ☆ ★ ★ 5/7 
SELSS 
(Wilkinson, 
1997) 
★ ☆ ★ ☆ N/A ☆ ★ ★ 
4/7 
Sembi (1998) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Solgajova 
(2017) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Stojanovic 
(2015) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Stone (2004)  ☆ ☆ ★ ☆ N/A ★ ★ ★ 4/7 
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Tang (2012) ★ ☆ ★ ★ N/A ☆ ★ ★ 5/7 
Tang (2013) ★ ☆ ★ ★ N/A ☆ ★ ★ 5/7 
Townend 
(2007) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Vicentini (2016) ☆ ☆ ★ ☆ N/A ☆ ★ ★ 3/7 
Vickery (2006) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Visser-Kelzer 
(2002) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Vuletic (2011) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Vuletic (2012) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Watanabe 
(1997) ☆ ☆ ★ ☆ N/A ☆ ★ ★ 3/7 
Wu (2017) ★ ☆ ★ ★ N/A ☆ ★ ★ 5/7 
Zalihic (2010) ★ ☆ ☆ ☆ N/A ☆ ★ ★ 3/7 
Zhao (1999) ★ ☆ ★ ☆ N/A ☆ ★ ★ 4/7 
Key: ★, low risk of bias; ☆, high risk of bias; N/A, not applicable  
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Table 3: Characteristics of included studies: interview methods 
Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Ajiboye, 2013, 
Nigeria 
Hospital/cross-
sectional/ 
all consecutive 
patients/ 
Mar 2009 – Feb 
2010 
I: stroke diagnosed by consultant 
neurologist, age ≥18 
 
E: past psychiatric history, too sick to be 
interviewed 
60.6 years (44.6) SCAN 
(interview) 
<1 to >5 
years  
83 10.8 (4.2, 17.5) 
 
GAD: 9.6 (3.3, 
16.0)  
Phobic 
disorder: 1.2 (0, 
3.6) 
Astrom, 1996, 
Sweden 
Hospital / cohort / 
consecutive / 1979-
1981 
I: ischaemic, haemorrhagic & TIA (CT) 
 
E: congenital mental handicap  
73 years (61) DSM-III-R (GAD) 2 weeks 
 
3 months 
 
1 year 
 
2 years 
 
3 years 
71 
 
70 
 
66 
 
57 
 
48 
2 weeks 28 (18–
39) 
78 70 3 m 31 
(21–42) 
83 66 1 y 24 
(14–35) 
86 57 2 y 25 
(13–36) 
86 48 3 y 19 
(7·7–30) 
Chinchaladze, 
2013, NR 
NR/NR/NR/NR NR 
 
NR DSM-IV 
(interview) 
NR 294 31.0 (25.7, 
36.2) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Chun, 2018, UK Hospital/cohort/ 
consecutive/NR 
I: ≥18 years, new stroke or TIA (clinical 
diagnosis), mental capacity to give 
informed consent, able to communicate 
in English over telephone  
 
E: SAH, subdural or extradural 
haematoma, ocular TIA, terminal stage 
of illness; difficult to follow up due to 
no fixed abode, current illicit drug or 
alcohol dependence  
70 years (60) SCID (interview) 3 months 175 21.7 (15.6, 
27.8) 
GAD only: 4.0 
(1.1, 6.9) 
Phobic disorder 
only: 10.3 (5.8, 
14.8) 
GAD + phobic 
disorder: 7.4 
(3.5, 11.3) 
Garikimukku, 
2015, India 
Hospital/ 
cross-sectional/ 
NR/2014 
I: ≥18 years, diagnosis of stroke   
 
E: other serious organic illness, previous 
history of psychiatric disorder, severe 
cognitive impairment 
NR MINI PLUS 
(interview) 
Acute 50 18.0 (7.4, 28.6) 
GAD: 18.0 (7.4, 
28.6) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Kneebone, 2016, 
UK 
Hospital/ 
cross-sectional/ 
all patients/NR 
I: ≥65 years, inpatients with stroke two 
weeks to six months previously, 
medically stable 
 
E: significant cognitive impairment 
(AMT ≤8, MMSE ≤24, or opinion of lead 
physician), aphasia, comorbid 
psychiatric disorder other than anxiety 
or depression 
80 years (52) SCID (interview) 3 days 
(range 1-7) 
69 11.6 (4.0, 19.1)  
Leppavuori, 2003, 
Finland 
Hospital / cross-
sectional / 
consecutive / NR 
I: Ischaemic stroke  
 
E: SAH, ICH, no clinical neurological 
examination, severe aphasia, refusal of 
psychiatric examination 
71 years (51) DSM-IV_GAD 3-4 months  277 21 (16–26) 
Morris, 1990, 
Australia 
Hospital / cohort / 
consecutive / NR 
I: ischaemia & haemorrhagic stroke 
(WHO) (CT) 
 
E: aphasia 
71 years (51) DSM-III 2 months  
 
1 year 
99 
 
56 
3·0 (0–6·4) 
 
5·4 (0–11) 
Mumladze, 2016, 
Georgia 
NR/cohort/ 
NR/NR 
NR NR DSM-IV 
(interview) 
Acute 168 17.3 (11.5, 23)  
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
OCSP, 1991, UK 
 
OCSP-II, 1990, UK 
Community / 
cohort / registry / 
1981-1986 
I: first-ever stroke (CT) 
 
E: recurrent stroke, TIA 
71 years (45) DSM-III (GAD) 1 month 
 
6 months 
 
1 year 
 
2-5 years 
89 
 
119 
 
112 
 
60 
1·1 (0, 3) 
 
0·8 (0, 3) 
 
0 (0, 0) 
 
20 (10, 30) 
 
Agoraphobia 
8·3 (1·3–15·3) 
GAD 5·0 (0–11) 
Simple phobia 
5·0 (0–11) 
Panic disorder 
2·0 (0–5) 
Oni, 2016, Nigeria Hospital/ 
cross-sectional/ 
consecutive/ 
2013-2014 
I: adult stroke survivors 
 
E: severe cognitive deficits 
57 years (54) SCAN 
(interview) 
28 <1 year 
9 1-2 years 
33 >2 years 
70 10.0 (3.0, 17.0) 
PCSS, 1995, 
Australia 
Community / 
cohort / ideal case 
finding / 1995-1996 
I: first-ever or recurrent stroke or TIA 
(WHO) 
73 (56) DSM-III 4 months 294 19 (14–23) 
Agoraphobia 16 
(12–20) 
GAD 3 (1–5) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Petrova, 2012, 
Russia 
Hospital / cohort / 
consecutive / NR 
I: stroke, admitted within 24 hours of 
onset.  
 
E: significant co-morbidity, cancer, 
amnesia 
70 years (48) DSM-IV 1, 7, 14 and 
28 days, 
and 3, 6 
and 12 
months 
post-stroke 
198 (overall period) 
GAD 33.3 (26.8, 
39.8) 
Phobias 22.2% 
 35 
 
Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Sagen, 2009, 
Norway 
Hospital/cohort/ 
consecutive/ 
2003-2005 
I: ischaemic stroke 
 
E: TIA, insufficient competence in 
Norwegian language, severe aphasia, 
psychosis, MMSE <20, terminal illness 
65 years (59) SCID (interview) 4 months 104 23.1 (15.0, 
31.2)  
GAD: 5.8 (1.3, 
10.3) 
PTSD: 2.9 (0, 
6.1) 
Specific phobia: 
8.7 (3.3, 14.1) 
Social phobia: 
2.9 (0, 6.1) 
Panic with 
agoraphobia: 
7.7 (2.6, 12.8) 
Panic without 
agoraphobia: 
2.9 (0, 6.1) 
Agoraphobia 
without panic 
disorder: 3.8 
(0.2, 7.5) 
OCD: 1.9 (0, 
4.6) 
Anxiety NOS: 1 
(0, 2.8) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Schottke, 2015, 
Germany 
Rehabilitation/ 
cross-sectional/ 
NR/NR 
I: acute cerebral infarction or 
intracerebral haemorrhage, 
neurological symptoms exceeding 24 
hours, precise documentation of lesion, 
admission to rehabilitation clinic 
capability to attend facilities and 
undergo structured interview in 
German 
 
E: severe communication disorders 
67 years (56) SCID (interview) 6 weeks  289 20.4 (15.8, 
25.0)  
GAD: 4.8 (2.4, 
7.3) 
Specific phobia: 
3.8 (1.6, 6) 
Social phobia: 
2.1 (0.4, 3.7) 
Panic with 
agoraphobia: 1 
(0, 2.2) 
Panic without 
agoraphobia: 
2.1 (0.4, 3.7) 
Agoraphobia 
without panic 
disorder: 4.5 
(2.1, 6.9) 
OCD: 2.1 (0.4, 
3.7) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Schultz, 1997, 
USA 
Hospital / cohort, 
consecutive / NR 
I: stroke 58 years (57) DSM-IV_GAD Acute 
phase 
 
3 months 
 
6 months 
 
12 months 
 
2 years 
142 
 
 
77 
 
79 
 
70 
 
66 
19 (13–25) 
 
 
77 3m 22 (13–
31) 
79 6m 25 (16–
35) 
70 12m 11 
(4·0–19) 
66 2y 18 (8·9–
27) 
Tang, 2002, Hong 
Kong 
Rehabilitation/ 
cross-sectional/ 
consecutive / 
1999–2000 
I: First-ever stroke (CT) 
 
E: TIA, SAH, history of 
neurological impairment, 
comprehension and 
communication deficits, length 
of stay <2 weeks 
71 years (45) DSM-III-R 25 days 157 0·6 (0–1·9) 
Verma, 2012, 
India 
Hospital/cross-
sectional/ 
NR/NR 
NR NR NR 1-6 months 100 24.0 (15.6, 
32.4) 
Zhang, 2011, NR Hospital/cross-
sectional/NR/NR 
NR NR CCND-3 
(interview) 
Acute 350 10.0 (6.9, 13.1) 
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Table 4: Characteristics of included studies: rating scale methods 
Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Ahlsio, 1984,  
Sweden 
Community/ cross-
sectional/ 
Consecutive / 1979 
I: CI, TIA, SAH (CT) 
 
E: Severe disability, aphasia, 
dementia 
71 years (60) Self-report 2 years 53 26 (15–38) 
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South London 
Stroke Register 
(SLSR): Ayerbe, 
2014, UK 
 
 
 
 
 
 
 
Crichton, 2016, 
UK 
Population/ 
cohort/all patients 
on register/Jan 
1995 – Dec 2009  
 
 
 
 
 
 
 
1995 – 2003 
I: stroke (WHO) 
 
E: severe cognitive or 
communication impairment 
53% male 
55% 
 
57% 
 
58% 
 
 
 
 
57% 
Median: 62 years 
(59) 
HADS-A >7 
 
 
 
 
 
 
 
 
 
 
HADS-A >7 
3 months 
1 year 
 
2 years 
3 years 
4 years 
5 years 
6 years 
 
7 years 
8 years 
 
9 years 
10 years 
10 years 
15 years 
1104 
1231 
 
901 
1096 
889 
659 
604 
 
470 
401 
 
296 
88 
409 
133 
At 3 months: 34.1 
(31.3, 36.9) 
At 1 year: 32.9 (30.3, 
35.5) 
At 2 years: 33.8 
(30.7, 36.9) 
At 3 years: 31.9 
(29.1, 34.7) 
At 4 years: 32.4 
(30.8, 38.1) 
At 5 years: 34.4 
(30.8, 38.1) 
At 6 years: 33.3 
(29.5, 37.0) 
 
At 7 years: 34.0 
(29.7, 38.3) 
At 8 years: 34.2 
(28.0, 38.8) 
 
At 9 years: 33.4 
(29.0, 38.8) 
At 10 years: 38.3 
(31.9, 44.6) 
At 10 years: 31.4 
(26.9, 36.3) 
At 15 years: 34.9 
(26.8, 43.0) 
Azanmasso, 2017, 
Benin 
Hospital/cross-
sectional/ 
NR/NR 
NR 
  
54.3 years HADS (cut off 
NR) 
 
>6 months 67 22.4 (12.4, 32.4) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Barker-Collo, 
2007, New 
Zealand 
Rehabilitation / 
cross-sectional / 
consecutive / NR 
I: ischaemic or Haemorrhagic 
stroke (CT) 
 
E: aphasia, non-native language 
speaker 
52 years (55) BAI>25 3 months  81 21 (11–32) 
Barker-Collo, 
2017, New 
Zealand 
Population/ 
cohort/all new 
hospitalised or 
non-hospitalised 
patients/2011-
2012 
I: stroke (WHO), resident of 
Auckland region, ≥16 years 
E: intracerebral haemorrhage, SAH, 
sensory or cognitive impairment, 
speech or language barrier, too 
unwell 
69.2 years 
(53) 
HADS-A >6 2 weeks 
1 month 
6 months 
1 year 
208 
353 
346 
365 
10.6 (8.4, 12.8) 
7.1 (5.7, 8.5) 
6.4 (5.0, 7.7) 
4.1 (1.4, 6.8) 
 
Beghi, 2009, Italy Hospital / cross-
sectional / 
consecutive / 2000-
2001 
I: stroke 
 
E: sufficient language for interview. 
MMSE > 18 
70 years (68) HAMA >17 > 2 years 82 12.2 (5.1, 19.3) 
Bergerson, 2010, 
Norway 
Rehabilitation / 
cross-sectional / 
mail-out all 
patients / 1998-
2001 
I: Ischaemic, ICH, SAH 
 
E: aphasia 
54 years (64) HADS-A>10 2-5 years 162 17 (11–22) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Bovim, 2016, NR Hospital/cohort/NR
/NR 
I: >18 years 
 
E: receiving palliative care 
76.8 years HADS-A >7 ≤14 days 390 63.6 (58.8, 68.4) 
Broomfield, 2014, 
UK 
Population/ 
cohort/all 
consecutive 
patients/ 
2012-2013 
I: on Glasgow LES database 
 
E: resident in care-home, 
housebound  
70.3 years (57) HADS-A >7 NR 4079 28.9 (27.5, 30.3) 
Broomfield, 2015, 
UK 
Community/ 
cross-sectional/ 
NR/2009-2010 
I: patients on primary care stroke 
registers, who agreed to an annual 
health check  
 
E: resident in nursing home, 
housebound, serious comorbidity 
70.4 years (55) HADS-A >7 NR 3831 16.0 (14.8, 17.2) 
Bruggiman, 2006,  
Switzerland 
Community/ cross-
sectional/ 
consecutive 
/ NR 
I: First-ever ischemic or 
hemorrhagic stroke 
 
E: NIHSS>3, history of 
psychiatric illness, neurologic 
comorbidity 
51 years (67) HADS-A >7 1 year 49 24 (12–37) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Buijck, 2012, 
Netherlands 
Rehabilitation/ 
cohort/all 
patients/2008 
I: all patients 
 
E: expected to be discharged within 
two weeks, critically ill 
79 years (54) NPI >0 NR 145 15.0 (9.2, 20.8) 
Carod-Artal, 
2009, Brazil 
Rehabilitation / 
cross-sectional / 
consecutive / 2007-
2008 
I: Ischaemic or haemorrhagic 
stroke (clinical diagnosis & 
radiological findings) 
 
E: TIA, subdural haematoma, 
dementia, aphasia, severe 
disability due to previous 
neurological disorder 
56 years (52) HADS-A>10 20 months  300 24 (19–29) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Castellanos-
Pinedo, 2011, 
Spain 
Hospital/cohort/NR
/2007-2008 
I: stroke (neuroimaging), patient 
has responsible caregiver 
 
E: previous dementia or cognitive 
decline (clinical record or IQCODE), 
cerebral haemorrhage or other 
suspected cause aetiology of brain 
injury, TIA, persistent coma or 
severe alteration of consciousness 
four weeks after stroke, death or 
appearance of new lesion before 
four weeks 
70 years (52) HAMA >5 4 weeks 89 33.7 (23.9, 43.5) 
Chanchaem, 
2013, Thailand 
NR/cross-sectional/ 
NR/2010-2012 
NR 62.5 years  HADS (cut off 
NR) 
NR 215 22.3 (16.7, 27.9) 
Crowley, 2017, 
UK 
Hospital-based 
acute unit and 
community-based 
stroke service 
/cohort/ 
consecutive/NR 
I: first stroke three months 
previous, able to communicate 
 
E: MMSE <18, dementia, significant 
premorbid psychiatric illness, 
premorbid alcohol or drug 
addiction  
62 years (66) HADS-A >7 3 months 35 39.0 (22.8, 55.2) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
D’Alisa, 2005, 
Italy 
Rehabilitation / 
cross-sectional / 
consecutive / 2002-
2004 
E: MMSE<24, aphasia 63 years (60) HADS-A>10 5 years  73 21 (11–30) 
D’Aniello, 2014, 
Italy 
Rehabilitation/ 
cross-sectional/ 
NR/NR 
I: first or second diagnosis of stroke 
 
E: global aphasia, behavioural 
disorders, dementia 
62 years (59) HADS-A >4 4 years 
(range 1-
20) 
81 55.6 (44.8, 66.4) 
De Weerd, 2011, 
Netherlands 
Hospital/cohort/ 
all patients/ 
2006-2007 
I: all patients admitted to 
department of neurology  
 
E: <65 years, referral to nursing 
home, rehabilitation centre, or 
another department 
77 years (44) HADS-A >7 12 months 57 9.1 (1.6, 16.6) 
De Weerd, 2012, 
Netherlands 
Hospital/cohort/ 
all patients/ 
2007-2008 
I: all ischaemic stroke patients 
 
E: <60 years, referral to nursing 
home, rehabilitation centre, or 
another department 
75 years (65) HADS-A >7 12 months 88 5.6 (0.8, 10.4) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Delva, 2017, 
Ukraine 
NR/cohort/ 
NR/NR 
I: acute stroke  
 
E: major illness that could cause 
secondary fatigue, alcohol abuse, 
consciousness impairment or 
MMSE <24, depressive or anxious 
disorders (HADS-A >10), severe 
aphasia or dysarthria, impaired 
language or written ability, mRS ≥4 
64 years (47) HADS-A >4 6 months 156 21.2 (14.8, 27.6) 
DeWit, 2008, 
England, Belgium, 
Switzerland, 
Germany 
Rehabilitation / 
cohort / 
consecutive / 2002-
2004 
I: first-ever stroke (WHO) (CT), 
RMA-GP<12 and/or leg trunk 
function <9 and/or arm function 
<13 
 
E: neurological impairments, 
prestrike BI<50, subdural 
haematoma, admitted to rehab 
centre 6 or more weeks post-
stroke 
70 years (53) HADS-A >7 2 months  
 
4 months 
 
6 months  
491 
 
478 
 
467 
25 (21–29) 
 
4m 23 (19–27) 
 
6m 21 (18–25) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Donnellan, 2010, 
Ireland 
Hospital / cross-
sectional / 
consecutive 
admissions / not 
stated 
I: first or recurrent stroke (WHO, 
CT) & FAST  ≥14 & Abbreviated 
Mental Test score ≥8 
 
E: TIA, SAH, traumatic intracranial 
haemorrhage, dementia, extreme 
critical illness  
Range 20-98 years 
[mean not 
reported] 
(51) 
HADS-A >7 1 month 
 
1 year 
 
107 
 
94 
 
35 (26–44) 
 
32 (24 - 42) 
 
Donnellan, 2016, 
Bahrain 
Hospital/ 
cohort/all 
consecutive/NR 
I: ≥18 years, first or recurrent 
stroke, ability to participate in 
interview, FAST ≥14 
 
E: TIA or related syndromes, 
aphasia, medically unstable, 
vascular dementia or pre-stroke 
cognitive impairment, TBI or 
traumatic intracranial or 
subarachnoid haemorrhage, visual 
or hearing impairment, 
neurodegenerative disease 
61 years (67) HADS (cut off 
NR) 
1-2 weeks 64 27.0 (16.1, 37.9) 
Elf, 2016, Sweden Hospital/cohort/ 
all patients/ 
2006-2007 
I: living in community three months 
post-stroke  
 
E: NR 
62 years (56) HADS-A >4 6 years 102 36.3 (26.9, 45.6) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Field, 2008, UK Hospital / cross-
sectional / all 
patients meeting 
criteria 
E: cognitive impairment, aphasia, 
acute medical problems 
72 years (53) HADS-A >10 <1 month 81 21 (12–30) 
Fure, 2006, 
Norway 
Hospital / cross-
sectional / 
consecutive / 2000-
2002 
I: stroke (CT) 
 
E: TIA, moderate to severe aphasia, 
consciousness 
69 years (63) HADS-A >7 1 week 178 26 (20–33) 
Galligan, 2016, 
Ireland 
Mixed (clinic, 
hospital, and 
support group)/ 
cross-sectional/ 
NR/NR 
I: ≥18 years, stroke (WHO) 
between one month and two years 
ago 
 
E: significant cognitive impairment, 
moderate to severe 
communication difficulties, major 
comorbid medical difficulties or 
acute health difficulties 
65 years (71) HADS (cut off 
NR) 
NR 98 36.7 (27.2, 46.3) 
Gangstad, 2009, 
UK 
Rehabilitation/ 
cross- sectional/all 
patients attending 
clinic 
approached 
meeting 
inclusion/ NR 
E: Cognitive impairment NR (NR) HADS-A>10 14 months 15 6·7 (0–19) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Ghika-Schmid, 
1999,  
Switzerland 
Rehabilitation/ 
cross- sectional/ 
consecutive / NR 
I: First-ever stroke only (CT or MRI) 60 years (NR) HAM-A>14 3 months  31 29 (13–45) 
Giaquinto, 2007, 
Italy 
Rehabilitation/ 
cross-sectional/ 
consecutive 
/2004–2005 
I: First-ever stroke (CT or MRI) 
 
E: TIA, SAH, previous stroke but 
not TIA, admission to rehab 
>three-week poststroke, severe 
comorbidity, mental or 
comprehension impairment 
70 years (46) HADS-A >5 10 days 132 42 (33–50) 
Gillespie, 1997, 
UK 
Community/ cross-
sectional/ mail-out 
to discharged 
patients/ NR 
I: Stroke (WHO) 
 
E: Communication difficulties, 
cognitive 
impairment, significant 
comorbidity, recent 
major life event unrelated to stroke 
69 years (66) HADS-A >8 7 months  44 25 (12–38) 
HSRS, 1999, 
Japan 
Community / 
cohort / registry / 
187 
I: all strokes 66 years (64) GHQ-60 > 4 
out of 7 on 
anxiety 
subscale 
2.5 years 66 43 (29–57) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Huzmeli, 2017, 
Turkey 
Hospital/ 
cross-sectional/ 
all patients/NR 
I: all patients with hemiplegic 
symptoms 
 
E: NR 
61 years (73) GAD-7 ≥15 6 months 
to 5 years  
30 33.3 (16.4, 50.2) 
Ibrahimagic, 
2005, Bosnia and 
Herzegovina 
Hospital / cohort / 
consecutive / NR 
I: Ischaemic stroke (CT) and able to 
complete self-report questionnaire  
65 years (50) Zung ≥50 2 days 
 
2 weeks 
40 
 
40 
30 (16–44) 
25 (12–38) 
Ibrahimagic, 
2013, Bosnia and 
Herzegovina 
NR/cross-
sectional/NR/ 
NR 
I: stroke (CT) 
 
E: NR 
65 years (50) Zung SAS ≥50 Acute 40 30.0 (15.8, 44.2) 
Jones, 2012, 
Tanzania 
Community/ 
cohort/all patients/ 
2003-2007 
I: first of recurrent stroke (WHO) 
 
E: neurological deficit cause by 
infection or space-occupying lesion 
67 years (48) HADS-A >7 36 months 
(range 6-
60) 
51 21.6 (10.3, 32.9) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Kim, 2017, South 
Korea 
Rehabilitation/ 
cohort/NR/NR 
I: ≥18 years, first stroke (clinical 
presentation and MRI), ICD-10 
codes 160-164, satisfactory 
cognitive function  
 
E: MMSE ≤10, MMSE 11-23 with 
physician confirmation of cognitive 
incompetence, TIA, severe auditory 
or visual impairment 
60 years (58) HADS-A >10 1 month 214 20.6 (15.2, 26.0) 
Knapp, 1998, UK Hospital / cross-
sectional / 
consecutive / NR 
I: stroke within past month, 
sufficient language and cognition 
for interview, named carer also 
willing to participate, living 
independently pre-stroke 
69 years (53) HADS-A >7 < 1 month 
 
1 month 
post-
discharge 
 
6 months 
post-
discharge 
30 
 
30 
 
 
 
30 
47 (29–65) 
 
27 (11–43) 
 
 
 
30 (14–47) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Kootker, 2016, 
Netherlands 
Hospital / cohort/ 
consecutive / 2011-
2013 
I: Diagnosis of clinically confirmed 
cerebral stroke; aged >=18; 
sufficient knowledge of Dutch 
language to complete assessments; 
within first week post-stroke 
 
E: Serious comorbid condition that 
might influence study outcomes; 
pre-stroke Barthel Index <=17; pre-
stroke Heteroanamnesis List 
Cognition >=1 
67 years (65) HADS-A >7 1 year 395 24.0 (19.0, 29.0) 
Langhorne, 2000, 
UK 
Rehabilitation/ 
cohort/ multi-
centre 
consecutive 
/ NR 
I: Stroke (WHO) within 
seven-days of onset 
76 years (52) Single 
question 
6 months 
post-
discharge 
 
18 months 
post-
discharge 
 
30 months 
post-
discharge 
220 
 
 
 
181 
 
 
 
155 
34 (28–40) 
 
 
 
44 (37–51) 
 
 
 
49 (41–57) 
Li, 2006, China Hospital / cross-
sectional / random 
selection / 2000-
2002 
I: Cerebral infarction 53 years (53) HADS-A >9 NR 91 31 (21–40) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Lincoln, 1998, UK Community/ cross-
sectional/ 74 
GP practices/ 
1994–1996 
I: Stroke (WHO) 76 years (67) HADS-A >10 1 month 84 26 (17–36) 
Lincoln, 2013, 
Belgium, UK, 
Switzerland & 
Germany 
Rehabilitation/ 
cohort/ 
consecutive/NR 
I: age 40-85, first stroke 
 
E: admitted >6 weeks after stroke, 
comorbid neurological 
impairments, poor prestrike 
functional ability (BI <50)  
68 years (54) HADS-A >7 6 years 220 29.0 (23.0, 35.0) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Liu, 2018, China Hospital/ 
cross-sectional/ 
consecutive/ 
2013-2014 
I: 18-80 years, admitted with seven 
days of first or recurrent stroke, 
absence of thrombolysis or 
interventional therapy; CAT, SOD, 
and MDA measured on admission 
 
E: previous history or family history 
of psychiatric disorders, severe 
aphasia or dysarthria, significant 
physical illness (listed), history of 
antipsychotic medication or 
vitamins,  
64 years (65) HAMA >7 1 month 203 24.0 (18.1, 29.9) 
Macniven, 2005, 
UK 
Rehabilitation/ 
cross-sectional/ 
two-week audit of 
all 
patients on ward/ 
NR 
E: Language problems 68 years (47) HADS-A >7 58.5 days 57 65 (42–87) 
Masskulpan, 2008  
& 
Kuptniratsaikul, 
2009, Thailand 
Rehabilitation/ 
cohort/ national 
registry / 2006 
I: Adult stroke patients 
 
E: Severe medical comorbidities, 
inability to communicate, 
dementia, schizophrenia or 
present psychotic episode 
62 years (59) HADS-A >10 24 days 
 
2 months 
327 
 
251 
5·8 (3·3–8·4) 
 
26 (20–31) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Mellon, 2013, 
Ireland 
NR/cohort/ 
consecutive/NR 
NR 
 
NR HADS (cut off 
NR) 
6 months 256 32.0 (26.3, 37.7) 
Merriman, 2007, 
UK 
Hospital / cross-
sectional / in-
hospital and postal 
mail-out to 
discharged patients 
/ NR 
I: adults & 1-12 months post-
stroke, able to complete self-report 
questionnaire 
 
E: dysphasia, acute medical 
problems 
74 years (56) HAD-A > 10 1-12 
months  
102 20 (12–27) 
Mihalov, 2016, 
Slovakia 
Hospital/cohort/ 
consecutive/ 
2013-2014 
I: NR 
 
E: persistent severe aphasia or 
cognitive deficit, using 
antidepressants for >6 months 
68 years (64) HADS-A >7 6 months 47 17.0 (6.3, 27.7) 
Moon, 2004, 
South Korea 
Hospital / cross-
sectional / 
consecutive / 2002 
I: stroke (MRI) NR (62) BAI>21 2 months  69 49 (37–61) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Morrison, 2000 & 
2005, UK 
Hospital / cohort / 
patient admitted to 
hospital / NR 
I: residual disability, pass screening 
test for cognitive & communicative 
problems  
69 years (51) HADS-A>10 <1 month 
 
2 months 
 
6 months 
 
3 years 
101 
 
78 
 
71 
 
38 
24 (15–32) 
 
21 (12–29) 
 
23 (13–32) 
 
26 (12–40) 
Mulroy, 2012, NR NR/cross-sectional/ 
NR/NR 
I: cognitively intact, mRS <3 
 
E: NR 
68 years (61) HADS-A >7 NR 94 14.9 (7.7, 22.1) 
Mutai, 2017, 
Japan 
Hospital/ 
cross-sectional/ 
NR/2012-2013 
I: ischaemic or haemorrhagic 
stroke (clinical or radiological 
findings) 
 
E: severe confusion, severe 
aphasia, severe moto 
complications with immobility 
74 years (66) HADS-A >10 2 weeks 101 24.7 (16.3, 33.1) 
 56 
 
Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Nakling, 2017, 
Norway 
Hospital/ 
cohort/all patients/ 
2008-2011 
I: stroke (MRI/CT), home-dwelling, 
NIHSS 2-26 or <2 with mRS ≥2  
 
E: severe psychiatric illness, alcohol 
or substance abuse, serious 
conditions interfering with 
rehabilitation process, insufficient 
knowledge of Norwegian language  
69 years (58) HADS-A >7 1 year 105 13.6 (7.0, 20.2) 
NEMSIS, 2004, 
Australia 
Community / 
cohort / ideal case 
finding method 
I: first and recurring stroke (WHO, 
CT or MRI) 
Unclear IDA-A (score 9-
15) 
3 months 
 
1 year 
 
2 years 
 
5 years 
475 
 
498 
 
201 
 
424 
13 (10–16) 
 
10 (7–13) 
 
11 (6–15) 
 
8·5 (6–11) 
Nijesse, 2017, 
Netherlands 
Hospital/ 
cross-sectional/ 
NR/2011-2013 
I: ≥18 years, stroke (clinically 
confirmed) in previous seven days 
 
E: other serious condition expected 
to interfere with study outcomes, 
BI <18, insufficient Dutch language 
ability, ≥1 on HLC pre-stroke  
67 years (64) HADS-A >7 2 months 350 20.4 (16.2, 24.6) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Ojagbemi, 2017, 
Nigeria 
Hospital/ 
cross-sectional/ 
consecutive/NR 
I: stroke (neuroimaging and clinical 
examination) 
 
E: severe communication 
difficulties or aphasia, dementia 
(CSID ≤20), mRS ≥3, significant 
comorbidity 
57 years (64) HADS-A >10 <1 month 391 19.7 (15.8, 23.6) 
Ponchel, 2016, 
France 
Hospital/cohort/ 
consecutive/NR 
I: ≥18 years, admitted for stroke 
(MRI), MRI within 72 hours of 
symptom onset 
 
E: prestrike dementia (IQCODE 
>64); malformed, traumatic, pure-
meningeal or intraventricular 
haemorrhage; patient under legal 
care of guardianship, 
contraindicated for MRI, inability 
to speak and understand French, 
neurological deficits including 
aphasia severe enough to impact 
understanding of questionnaires or 
tests 
64 years (61) HAMA >6 6 months 153 41.8 (34, 49.6) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Raju, 2010, India Hospital / cross-
sectional / patients 
completing at least 
1 month clinical 
follow-up / 2008-
2010  
I: first-ever ischaemic & 
haemorrhagic stroke (WHO) (CT or 
MRI), at least 1 month post-stroke 
 
E: history of psychoactive 
substance abuse, dementia, 
psychiatric comorbidity, aphasia 
54 years (70) HADS-A>10 1.5 years 162 11 (6·3–16) 
Sampson, 2003, 
UK 
Hospital / case-
control / recruit 
from 6 stroke units 
/ NR 
I: Ischaemic or haemorrhagic 
stroke 
 
E: Cognitive impairment, 
dysphasia, too unwell or with 
terminal illness, MRSA infection 
NR HADS-A>9 NR 69 26 (14–38) 
SELSS, 1997, UK Community / 
cohort/ registry / 
1989-1990 
I: first-ever stroke in persons <75 
including those who did not survive 
initial event.  
71 (54) HADS >9 5 years 96 31 (22–41) 
Sembi, 1998, UK Rehabilitation/ 
cross-sectional/ 
recruited from 
three rehabilitation  
sites/ 1995–1996 
I: adults, first-ever stroke or 
TIA, able to complete self-report 
Questionnaire 
 
E: Dysphasia 
66 years (NR) HADS-A >10 18 months  61 15 (5·9–24) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Solgajova, 2017, 
NR 
Hospital/cross-
sectional/ 
NR/2015-2016 
I: first stroke, lucid consciousness, 
oriented, informed consent given 
 
E: aphasia 
67 years (60) HADS-A >7 NR 74 16.0 (7.6, 24.4) 
Stojanovic, 2015, 
Bosnia and 
Herzegovina 
Hospital/cross-
sectional/ 
NR/NR 
I: first stroke with macroscopic 
lesions in prosencephalon on CT 
 
E: comorbid state (heart 
decompensation, unstable angina, 
MI in previous year, infective, 
malignant, or immunological 
diseases), NIHSS, >10, moderate to 
severe dysphasia   
Range 44–87 (50)  HAMA >13 NR 118 17.8 (10.9, 24.7) 
Stone, 2004, UK Hospital / nested 
cross-sectional / 
consecutive / 2004 
E: severe stroke with high risk of 
death, dementia, aphasia, cognitive 
impairment, patients living alone, 
carer unable to talk with 
researcher 
72 years (49) HADS-A>7 1 month 89 20 (12–29) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Tang, 2012, Hong 
Kong  
Hospital/cohort/ 
all admissions/ 
2004-2009 
I: first or recurrent acute ischaemic 
stroke with MRI 
 
E: history of CNS diseases or 
dementia, physical frailty, 
recurrent stroke within follow up 
period, aphasia, severe auditory or 
visual impairment, non-Chinese 
ethnicity or non-Cantonese 
speaking, MMSE <20, history of 
anxiety or other psychiatric 
disorder, history of alcohol or drug 
abuse 
66 years (61) HADS-A >7 1-5 months 693 6.1 (4.3, 7.9) 
Tang, 2013, Hong 
Kong 
Hospital / cross-
sectional / 
consecutive / 2008-
2011 
I: Chinese ethnicity; Cantonese as 
primary language; adult; confirmed 
stroke (CT) within 7 days of 
admission.  
 
E: TIA, SAH CH or SDH; history of 
other CNS condition; MMSE <20; 
aphasia; physical frailty; severe 
auditory or visual impairment; 
recurrent stroke.  
66 years (59) HADS-A >7 3 months 374 23.0 (18.7, 27.3) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Townend, 2007, 
Australia 
Hospital / cohort / 
consecutive / NR 
I: Ischaemic or haemorrhagic 
stroke 
 
E: dysphagia, MMSE<20, reduced 
level of consciousness 
76 years (49) HADS-A>8 5 days 
 
1 month 
 
3 months 
 
125 
 
112 
 
105 
4·8 (1·1–8·6) 
 
8·0 (3·0–13) 
 
14 (7·6–21) 
Vicentini, 2017, 
Brazil 
Hospital/cross-
sectional/ 
NR/2014-2015 
I: 45-80 years, first ischaemic 
stroke (CT) 
 
E: severe aphasia or dysarthria, 
history of psychiatric or 
neurological disorders 
NR BAI >11 Acute 37 11.8 (1.4, 22.2) 
Vickery 2006,  
USA 
Rehabilitation/ 
cross-sectional/ 
sample 
of admitted 
patients/ NR 
I: Stroke 
 
E: history of comorbid dementia, 
Non-stroke neurological process, 
acute delirium, severe psychiatric 
disturbance 
69 years (45) AMAS >64 20 days 141 7·8 (3·4–12) 
Visser-Keizer, 
2002,  
Netherlands 
Community/ cross-
sectional/ 350 
GP clinics/ NR 
I: First-ever ischemic stroke (CT) 
 
E: neurologic or psychiatric history, 
history of alcohol or drug abuse, 
insufficient language and cognitive 
ability for assessment, aphasia 
67 years (59) HADS-A >5 3 months 113 14 (7·7–21) 
 62 
 
Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Vuletic, 2011, 
Croatia 
Hospital/cross-
sectional/all 
patients/2008 
I: first stroke (CT) in previous three 
months 
 
E: recurrent stroke, major medical 
illness, alcohol abuse, decreased 
level of consciousness, dysphasia, 
severe cognitive impairment 
62 years (57) HADS (cut off 
NR) 
1-5 months 35 37.0 (21, 53.0) 
 
Vuletic, 2012, 
Croatia 
Hospital/cross-
sectional/all 
patients/2006 
I: first stroke (CT) 
 
E: TIA, previous emotional 
problems, severe aphasia, clouding 
of consciousness 
71 years (50) HADS (cut off 
NR) 
3-5 days 40 40.0 (24.8, 55.2) 
Watanabe, 1984, 
Japan 
Hospital / cross-
sectional / random 
selection/ NR 
E: aphasia, dementia 57 years (57) TMAS 6 months 35 51 (35–68) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Wu, 2017, China Hospital/cross-
sectional/ 
NR/2013-2014 
I: 18-80 years, acute stroke 
(CT/MRI) 
 
E: decreased consciousness, severe 
cognitive dysfunction, aphasia, 
dysarthria, history of anxiety or 
other psychiatric disorders, history 
of stroke or other CNS disease 
63 years (63) HAMA >7 ≤7days 226 26.5 (20.7, 32.3) 
Zahilic, 2010, NR NR/cross-sectional/ 
NR/2008-2009 
I: first cerebral stroke  
 
E: comorbidity which could 
influence development of 
depression, “both cerebral and 
heart stroke”  
72 years (55) HADS-A >7 NR 202 28.2 (22, 34.4) 
Zhao, 1999, China Hospital / cross-
sectional / 
consecutive / NR 
I: first-ever stroke (Chinese 
cerebral vascular disease 
symposium of 1995 definition) 
 
E: aphasia, mental disorder, 
epilepsy, mental retardation, 
cerebral trauma 
63 years (61) Zung SAS>49 1 month 206 18 (13–24) 
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Study name or 
author, 
year published, 
Location 
Setting/design/ 
recruitment/ 
year of study 
Inclusion (I)/exclusion (E) Mean age (% male) Method of 
measuring 
anxiety 
Time post-
stroke 
n Rate of anxiety 
(95% CI) 
Abbreviations: AMT, Abbreviated Mental Test; BAI, Beck Anxiety Inventory; BI, Barthel Index; CAT, catalase; CCND-3, China psychiatric 
disorders classification and diagnosis standard version 3; CNS, central nervous system; CSID, Community Screening Interview for 
Dementia; CT, computed tomography used to diagnose stroke; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition; FAST, Frenchay Aphasia Screening Test; GAD-7, General Anxiety Disorder 7-item scale; HADS, Hospital Anxiety and Depression 
Scale; HAMA, Hamilton Anxiety Rating Scale; HLC, Heteroanamniesis List Cognition; ICD-10, International Classification of Diseases, 10th 
Edition; IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly; LES, Local Enhanced Service; MDA, malondialdehyde; MINI 
PLUS, Mini-International Neuropsychiatric Interview-Plus; MMSE, Mini Mental State Examination; mRS, modified Rankin Scale; NIHSS, 
National Institutes of Health Stroke Scale; NPI, Neuropsychiatric Inventory; NR, not reported; SCAN, Schedule for Clinical Assessment 2.1; 
SCID, Structured Clinical Interview for DSM-IV Disorders; SOD, superoxide dismutase; WHO, World Health Organisation definition of 
stroke; Zung SAS, Zung Self-rated Anxiety Scale 
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Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
1 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  2 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
2 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
2 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
3 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
3 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
appendix 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
3 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
3 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
3 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
3 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  3 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
3 
 
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
3 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
n/a 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
4 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
tables 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  tables 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Tables 
and 
figures 1 
and 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  5 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  6 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  5-6 
DISCUSSION   
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
6-8 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
6-8 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  6-8 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
9 
 
 
 
 
   
 
